NJ Center for Clinical and Translational Sciences

新泽西临床和转化科学中心

• 批准号: 7216033
• 负责人: KATHLEEN W. SCOTTO
• 金额: $ 23.33万
• 依托单位: UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-21 至 2008-09-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7216033
• 关键词: Internet; NIH Roadmap Initiative tag; clinical research; curriculum; educational resource design /development; health science research; health science research support; information dissemination; information systems; interdisciplinary collaboration; science education

DESCRIPTION (provided by applicant): New Jersey is uniquely suited as the host to a unique consortium of shareholders committed to the rapid and effective translation of basic biomedical discoveries into new tools for prevention, diagnosis and treatment of disease. It has a dense and diverse urban population, one of the largest biotechnology and pharmaceutical industries in the world, a government committed to new innovations and technology and a community with a strong legacy of advocacy for biomedical advances. The New Jersey Center for Clinical and Translational Sciences (NJCCTS) will tap into these unique resources, bringing together scientists, clinicians, industry, community and the State to forge new and novel alliances that will transform the process of clinical/ translational research in our State and country. We will work as teams, determining needs, directing research to fulfill those needs and cooperating to anticipate and remove the traditional impediments to success. We believe that this paradigm shift from a supply-driven to a user-driven prioritization of research goals will transform the way we accomplish the translation of basic scientific discoveries into cures. Importantly, as part of the process, we will train the teams of the future, so that what seems novel and innovative to us today will be common practice for the next generation. As part of the planning process, we propose to: 1) Develop the administrative structure that will support and nurture the growth of the NJCCTS, assemble and empower its shareholders, define its research directions, and define the critical attributes required for the Director of this unique and novel consortium; 2) Design a core curriculum that will provide the training necessary to develop a novel team approach to clinical/translational research. 3) Develop the hub of the NJCCTS, a research core facility that will nurture young and/or new clinical/translational investigators, provide an entry point for industry collaborators, and act as a central "matchmaker" - facilitating collaborations, identifying resources and moving projects through the pipeline. 4) Establish a Faculty Development Committee to devise a plan to ensure that team scientists are appropriately incentivized and rewarded and 5) Craft a web-based information system that will allow for seamless interactions among our partner institutions and with the national CTS consortium.

描述（由申请人提供）：新泽西是唯一适合作为主机到一个独特的股东财团致力于快速和有效的基本生物医学发现转化为预防，诊断和治疗疾病的新工具。它拥有密集而多样化的城市人口，世界上最大的生物技术和制药工业之一，致力于新创新和技术的政府以及倡导生物医学进步的强大遗产的社区。新泽西临床和转化科学中心（NJCCTS）将利用这些独特的资源，汇集科学家，临床医生，行业，社区和国家，建立新的和新颖的联盟，将改变我们国家和国家的临床/转化研究过程。我们将作为团队工作，确定需求，指导研究以满足这些需求，并合作预测和消除成功的传统障碍。我们相信，这种从供应驱动到用户驱动的研究目标优先级的范式转变将改变我们将基础科学发现转化为治疗方法的方式。重要的是，作为这一过程的一部分，我们将培训未来的团队，以便今天对我们来说新颖和创新的东西将成为下一代的普遍做法。 作为规划过程的一部分，我们建议：1）制定行政结构，以支持和培育NJCCTS的发展，聚集和授权其股东，确定其研究方向，并确定这个独特而新颖的财团的董事所需的关键属性; 2）设计一个核心课程，将提供必要的培训，以开发一个新的团队方法，以临床/转化研究。3)开发NJCCTS的中心，这是一个研究核心设施，将培养年轻和/或新的临床/翻译研究人员，为行业合作者提供切入点，并充当中央“媒人”-促进合作，确定资源并通过管道移动项目。4)建立一个教师发展委员会，制定一项计划，以确保团队科学家得到适当的激励和奖励，并5）制作一个基于网络的信息系统，使我们的合作伙伴机构之间的无缝互动，并与国家CTS财团。